Bispecific PD-1/TIGIT Binding Protein for Stronger Tumor Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune therapies targeting PD-1 and TIGIT receptors have limitations in effectively enhancing T cell activation and tumor cell elimination, necessitating a more potent and specific dual-targeting approach.
Innovation Solution
Development of a bispecific binding protein that simultaneously targets PD-1 and TIGIT receptors, comprising specific variable domains with defined amino acid sequences, to enhance T cell activation and tumor cell recognition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monospecific antibodies targeting PD-1 or TIGIT are used, then T cell activation is enhanced, but tumor cell elimination is insufficient
Solution Approach 1:
The patent combines two monospecific antibody functions into a single bispecific antibody molecule that simultaneously targets both PD-1 and TIGIT receptors. This merging approach allows the antibody to enhance T cell activation while improving tumor cell elimination efficacy through dual-targeting, resolving the contradiction between therapeutic effectiveness and molecular complexity by integrating multiple functions into one unified structure.
Solution Approach 2:
The bispecific antibody is designed with multi-functionality to simultaneously bind PD-1 and TIGIT receptors, enabling it to perform multiple therapeutic actions: blocking PD-1/PD-L1 interaction, blocking TIGIT/CD155 interaction, and enhancing T cell activation. This universal approach allows one antibody molecule to achieve comprehensive anti-tumor effects that would require multiple separate antibodies, improving efficacy without proportionally increasing complexity.
2Reliability
If dual-targeting approach is implemented, then tumor cell elimination is improved, but manufacturing complexity increases
Solution Approach 1:
The bispecific antibody is constructed using segmented modular domains, with distinct variable regions (VH1-VL1 for PD-1, VH2-VL2 for TIGIT) that can be independently designed and optimized. This segmentation allows for systematic production approaches where each domain can be engineered separately and assembled into the complete bispecific molecule, facilitating manufacturing while maintaining dual-targeting efficacy.
Solution Approach 2:
The patent employs parameter changes in the antibody structure, specifically using different constant region configurations (IgG1, IgG2, IgG3, or IgG4) and various domain arrangements to optimize both therapeutic performance and manufacturability. By adjusting these structural parameters, the antibody can be tailored for optimal production characteristics while preserving its dual-targeting anti-tumor efficacy.
Data Source
AI summary
The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 (“PD-1”) and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.